Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Mepsevii Coverage Criteria | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C17942-A

    Mepsevii (vestronidase alfa-vjbk) Coverage Criteria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C17942-A alerts

    Get alerted when Policy C17942-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage criteria for intravenous Mepsevii in members with Mucopolysaccharidosis VII (MPS VII, Sly syndrome), including therapy criteria, documentation, dosing, prescriber, age, duration, and site-of-care requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyMepsevii (vestronidase alfa-vjbk) Coverage Criteria
    Policy CodePolicy C17942-A
    Change TypeNo material change
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionObtain prior authorization and document the covered MPS VII indication, initial criteria, qualified specialist involvement, dosing, age, and site-of-care requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MPS VIICovered disease indication
    5 months+Minimum member age
    4 mg/kg q2wDose
    12 monthsAuthorization duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    IV
    Route
    60 minPost-infusion observation

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Documented diagnosis of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).
    • ONE of the following

      • Documentation that the diagnosis was confirmed by enzyme activity assay showing beta-glucuronidase (GUSB) deficiency.
      • Documentation that the diagnosis was confirmed by genetic testing showing a mutation of chromosome 7q21.11.
      • For members diagnosed through newborn or sibling screening: elevated glycosaminoglycans (GAGs) at two times the upper limit of normal (2x ULN) and two mutations consistent with MPS VII.
    • At least ONE of the following symptoms consistent with MPS VII

      • Enlarged liver and spleen.
      • Joint limitations.
      • Airway obstruction or pulmonary dysfunction.
    • Documentation of baseline values for ALL of the following

      • Urinary glycosaminoglycan (uGAG).

        Documentation required.

      • For members 6 years or older: ONE of the following

        • 6-minute walk test (6-MWT).
        • Percent predicted forced vital capacity (FVC).
      • For members younger than 6 years of age: ONE of the following

        • Upper airway obstruction during sleep.
        • Cardiac status.

    Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Documentation of positive response or disease stability compared with baseline (prior to therapy), evidenced by ALL of the following

      • Decreased urinary glycosaminoglycan (GAG) levels.

        Documentation required.

      • ONE of the following age-appropriate measures

        • Members 6 years or older: ONE of the following

          • 6-minute walk test (6-MWT).
          • Percent predicted forced vital capacity (FVC).

    Prescriber and Administration Requirements

    All of the following prescriber and administration requirements must be met:

    ALL of the following

    • Prescribed by, or in consultation with, a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, a physician who specializes in the treatment of lysosomal storage disorders, or a physician experienced in the management of mucopolysaccharidoses (MPS).

      If prescribed in consultation, consultation notes must be submitted with the initial request and reauthorization requests.

    • Member is 5 months of age or older.>= 5 months
    • Dose is 4 mg/kg once every 2 weeks.4 mg/kg every 2 weeks
    • Infusion is administered in a pharmacy or medical benefit setting at a non-hospital facility-based location, consistent with the Molina Health Care Site of Care program.

    All other uses of Mepsevii (vestronidase alfa-vjbk) are considered experimental or investigational and follow Molina's Off-Label policy.

    Initial Therapy Criteria

    Continuation Therapy Criteria

    MPS VII Continuation Therapy

    Continuation therapy requires all of the following:

    MPS VII continuation therapy

    • Response or disease stability compared with baseline

      • Urinary glycosaminoglycan (GAG) levels have decreased.Decreased uGAG
      • Age-appropriate clinical or functional outcome

        • Members 6 years or older

          • Six-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC) demonstrates response or stability.

    Billing and Coding

    Billing CodeHCPCS
    J3397Injection, vestronidase alfa-vjbk, 1mg

    Prior Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for Mepsevii (vestronidase alfa-vjbk). The request must establish the covered indication of Mucopolysaccharidosis VII (MPS VII, Sly syndrome) and satisfy all applicable initial medical-necessity criteria and administrative requirements.

    • Submit the diagnosis, confirmatory testing, qualifying symptoms, and required baseline documentation.
    • Include member-specific dosing information and comply with prescriber, age, quantity, and site-of-care requirements.
    Documentation Required

    Submit Complete Medical Documentation

    Molina may require additional documentation for coverage determination, quality improvement, and fraud, waste, and abuse prevention. Submit records that support medical necessity, non-investigational use, and the provider's authority to order or administer the drug.

    Disease and Treatment Background

    Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome, is an autosomal recessive lysosomal storage disorder caused by deficient beta-glucuronidase (GUSB) activity. This deficiency leads to incomplete degradation and accumulation of glycosaminoglycans, contributing to cellular and organ dysfunction. Clinical manifestations may include hepatosplenomegaly, joint limitations, airway obstruction, and pulmonary dysfunction. Mepsevii is used as intravenous enzyme replacement therapy for pediatric and adult patients with MPS VII.

    Policy Definitions

    MPS VII
    TermMucopolysaccharidosis VII (MPS VII)
    Also calledSly syndrome
    Associated deficiencyBeta-glucuronidase (GUSB) deficiency
    uGAG
    TermUrinary glycosaminoglycan (uGAG)
    PurposeMeasurement of urinary glycosaminoglycans
    Policy useDocumented at baseline and used for follow-up assessment

    Dose and Quantity Limits

    Quantity Limits
    DrugMepsevii (vestronidase alfa-vjbk)
    Dose4 mg/kg per dose
    FrequencyOnce every 2 weeks

    Administration Site Requirements

    Billing Rule

    Use an approved infusion site

    Administer infused Mepsevii under the Molina Site of Care program in a non-hospital facility-based location for pharmacy or medical benefit coverage.

    Policy Summary
    PayerMolina Healthcare
    PolicyMepsevii (vestronidase alfa-vjbk) Coverage Criteria
    Policy CodePolicy C17942-A
    Change TypeNo material change
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionObtain prior authorization and document the covered MPS VII indication, initial criteria, qualified specialist involvement, dosing, age, and site-of-care requirements.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaBilling and CodingPrior Authorization and DocumentationDisease and Treatment BackgroundPolicy DefinitionsDose and Quantity LimitsAdministration Site Requirements
    Growth velocity.
  1. Mental development.
  2. Forced vital capacity (FVC).
  3. Hepatosplenomegaly.
  4. 6-minute walk test (6-MWT).
  5. Hepatosplenomegaly.
  6. Improvement in upper airway obstruction during sleep.
  7. Cardiac status.
  8. Members younger than 6 years of age: ONE of the following

    • Decreased growth velocity.
    • Mental development.
    • Forced vital capacity (FVC).
    • 6-minute walk test (6-MWT).
  9. Prescriber attests to, or clinical reviewer has found, no evidence of intolerable adverse effects or drug toxicity, including anaphylaxis or severe allergic reactions.
  10. The Site of Care Utilization Management Policy applies to Mepsevii. See Specialty Medication Administration Site of Care Coverage Criteria (molinamarketplace.com) for site-of-care requirements.

    Hepatosplenomegaly demonstrates response or stability.
  11. Upper airway obstruction during sleep has improved or remains stable.
  12. Cardiac status demonstrates response or stability.
  13. Members younger than 6 years

    • Decreased growth velocity demonstrates response or stability.
    • Mental development demonstrates response or stability.
    • Forced vital capacity (FVC) demonstrates response or stability.
    • Six-minute walk test (6-MWT) demonstrates response or stability.
  14. The prescriber attests to, or a clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.No intolerable toxicity

    Examples include anaphylaxis and severe allergic reactions.

  15. Patient medical records and relevant test results.
  16. Credentials of the provider ordering or performing the drug or service.
  17. Any additional information requested for case-by-case review.
  18. Documentation Required

    Provide Member-Specific Dosing Data

    When Mepsevii is dosed by weight, body surface area, or another member-specific measurement, the applicable measurement must be submitted as part of the medical-necessity review.

    • Provide the member's current weight, body surface area, or other measurement used to calculate the dose.
    • The requested dose is 4 mg/kg once every 2 weeks.
    Documentation Required

    Initial Clinical Documentation

    For initial therapy, document confirmed MPS VII and at least one qualifying symptom, together with the required pretreatment baseline measures.

    • Document MPS VII (Sly syndrome).
    • Confirm the diagnosis by enzyme activity assay demonstrating beta-glucuronidase (GUSB) deficiency or by genetic testing showing a mutation of chromosome 7q21.11. For members diagnosed through newborn or sibling screening, elevated GAGs and two mutations consistent with MPS VII may support diagnosis; some members may have GAGs only 2 times the upper limit of normal.
    • Document at least one symptom consistent with MPS VII: enlarged liver and spleen, joint limitations, airway obstruction, or pulmonary dysfunction.
    • Document baseline urinary glycosaminoglycan (uGAG).
    • For members age 6 years or older, document a baseline 6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC).
    • For members younger than 6 years, document at least one age-appropriate baseline measure: upper-airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-MWT.

    Unsupported block type: documentation

    Documentation Required

    Submit Consultation Notes

    If Mepsevii is prescribed in consultation, submit the consultation notes with both the initial request and each reauthorization request.

    • The prescriber must be, or consult with, a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, physician specializing in lysosomal storage disorders, or physician experienced in managing mucopolysaccharidoses (MPS).
    Denial Risk

    Insufficient or Unsupported Documentation

    Molina may deny reimbursement or take other appropriate action when submitted documentation does not support medical necessity, non-investigational use, benefit coverage, or appropriate billing and utilization.

    • Documentation must support that the drug or service is medically necessary and not investigational or experimental.
    • Documentation must support that the service is within the member's benefits.
    • Inappropriate or excessive billing or other practice patterns may result in denial or additional action.
    Denial Risk

    Initial Criteria Not Met

    The initial request may be denied when the diagnosis, confirmatory testing, qualifying symptoms, or required baseline documentation is absent or does not meet the policy requirements.

    • MPS VII diagnosis is not documented.
    • Confirmatory enzyme activity or genetic testing is not documented, and no applicable newborn- or sibling-screening evidence is provided.
    • No qualifying MPS VII symptom is documented.
    • Required baseline uGAG and age-appropriate functional or clinical measures are not documented.
    Denial Risk

    Continuation Criteria Not Met

    Reauthorization may be denied when the record does not demonstrate positive response or disease stability compared with the pretreatment baseline, or when treatment-related toxicity is not adequately addressed.

    • No decreased urinary GAG or other required response or stability evidence is documented.
    • Required age-appropriate functional or clinical measures are missing.
    • Intolerable adverse effects or drug toxicity are present or have not been adequately assessed.
    Billing Rule

    Administrative and Administration Restrictions

    Authorization and administration are subject to age, qualified-prescriber, dosing, and site-of-care restrictions.

    • Member must be 5 months of age or older.
    • Prescription must be by, or in consultation with, a qualified specialist or physician experienced in treating MPS.
    • Dose is 4 mg/kg once every 2 weeks.
    • Infusion is recommended under pharmacy or medical benefit coverage in a non-hospital facility-based location in accordance with Molina's Site of Care program.
    • Molina's Site of Care Utilization Management Policy applies to Mepsevii.
    Denial Risk

    Non-MPS VII Use

    Uses of Mepsevii other than treatment of MPS VII are considered experimental or investigational and follow Molina's Off-Label policy.

    • There are no labeled contraindications to Mepsevii identified in the policy.
    6-MWT
    TermSix-minute walk test (6-MWT)
    PurposeAge-appropriate functional measure for members with MPS VII
    Use in assessmentUsed as a baseline and follow-up clinical or functional outcome measure
    FVC
    TermPercent predicted forced vital capacity (FVC)
    PurposeAge-appropriate pulmonary measure
    Use in assessmentUsed as a baseline and follow-up clinical or functional outcome measure
    MPS VII
    TermMucopolysaccharidosis VII (MPS VII)
    Also calledSly syndrome
    Disease typeAutosomal recessive lysosomal storage disorder involving deficient beta-glucuronidase activity
    GAGs
    TermGlycosaminoglycans (GAGs)
    Effect of beta-glucuronidase deficiencyGAGs are partially degraded
    ResultGAG fragments accumulate in lysosomes and eventually contribute to cellular and organ dysfunction